Status | Study |
Terminated |
Study Name: A Study of AK0529 in Infants Hospitalized With RSV Condition: Respiratory Syncytial Virus Infections Date: 2015-05-27 Interventions: Drug: AK0529 AK0529 pellets for oral administration |
Completed |
Study Name: Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection Condition: Respiratory Syncytial Virus Infections Date: 2015-03-09 Interventions: Drug: Placebo Participants wil |
Active, not recruiting |
Study Name: Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Condition: Respiratory Syncytial Virus Infections Date: 2014-12-21 Interventions: Drug: REGN2222 Drug: Placebo |
Completed |
Study Name: A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model Condition: Respiratory Syncytial Virus Infections Date: 2014-03-20 Interventions: Drug: ALS-008176 Drug: vehicle |
Completed |
Study Name: Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) Condition: Respiratory Syncytial Virus Infections Infections, Epidemics Date: 2013-07-26 |
Completed |
Study Name: ALX-0171 Safety Study in Adults With Hyperresponsive Airways Condition: Respiratory Syncytial Virus Infection Date: 2013-07-24 Interventions: Biological: ALX-0171 Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maxim |
Completed |
Study Name: Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age Condition: Respiratory Syncytial Virus Infections Date: 2012-12-07 |
Completed |
Study Name: Surveillance of Synagis in Korean Pediatric Patients Condition: Respiratory Syncytial Virus Infection Date: 2011-12-15 |
Completed |
Study Name: Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Condition: Respiratory Syncytial Virus Infection Date: 2011-09-12 Interventions: Drug: Palivizumab Other Names: ABT-315 Synagis |
Completed |
Study Name: The Development of a Human Model of Respiratory Syncytial Virus Infection Condition: Respiratory Syncytial Virus Infections Respiratory Viral Infect Date: 2011-05-05 Interventions: Biological: RSV A Memphis 37 Intranasal administration |